Serum Selenium Concentrations In Patients Research Articles

Proteomic and transcriptomics profiles of serum selenium concentrations in patients with heart failure are associated with immunoregulatory processes

Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Dutch Research Council, through the Open Competition ENW-KLEIN grant Background Low selenium concentrations are associated with worse outcomes in patients with heart failure (HF). However, the underlying pathophysiologic mechanisms remain incompletely understood. Therefore, we aimed to contrast serum selenium concentrations to blood proteomic and transcriptomic profiles in patients with HF. Methods Circulating proteins, whole blood transcriptomics and serum selenium measurements in a cohort of 2328 patients with worsening HF (BIOSTAT-CHF) were utilized to assess underlying pathophysiology. Penalized linear regression and gene expression analysis were used to assess proteins and transcriptomics profiles based on selenium concentrations, respectively. String database v11.5 was used for enrichment analyses. Additionally analyses of the association between genes encoding selenoproteins in relation to serum selenium and all-cause mortality were performed. Potential causality was investigated by supplementing human peripheral blood mononuclear cells (PBMCs) with selenium and measuring the concentrations of 18 different cytokines. Results From 356 biomarkers and 20 clinical features, the penalized linear regression model yielded 44 variables with <5% marginal false discovery rate as predictors of serum selenium. Biomarkers associated positively with selenium concentrations included: epidermal growth factor receptor (EGFR), IFN-gamma-R1, CD4, GDF15, and IL10. Biomarkers associated negatively with low selenium concentrations included: PCSK9, SPON2, TNFSF13, FGF21 and PAI. In addition, 148 RNA transcripts were found differentially expressed between high and low Se status (Padj.<0.05; fold change<|0.25|). Enrichment analyses of the selected biomarkers and the selected RNA transcripts identified similar enriched processes, including regulation processes of leukocyte differentiation and activation, as well as cytokines production. The expression of two gene encoding selenoproteins (MSRB1 and GPX4) were strongly correlated with serum selenium after multiple corrections, while GPX4, SELENOK, and SELENOS were associated with prognosis. In the in-vitro setting, PBMCs supplemented with selenium showed significantly lower abundance of several (pro-)inflammatory cytokines. Conclusion These data suggest that immunoregulation is an important mechanism through which selenium might have beneficial roles in heart failure. The beneficial effects of higher serum selenium concentrations are likely because of global immunomodulatory effects on the abundance of cytokines. MSRB1 and GPX4 are interesting targets as potential modulators of this immunoregulatory effect of selenium and should be pursued in future research.Cytokines concentrations

Biomarker and transcriptomics profiles of serum selenium concentrations in patients with heart failure are associated with immunoregulatory processes

BackgroundLow selenium concentrations are associated with worse outcomes in heart failure (HF). However, the underlying pathophysiologic mechanisms remain incompletely understood. Therefore, we aimed to contrast serum selenium concentrations to blood biomarker and transcriptomic profiles in patients with HF. MethodsCirculating biomarkers, whole blood transcriptomics and serum selenium measurements in a cohort of 2328 patients with HF were utilized. Penalized linear regression and gene expression analysis were used to assess biomarker and transcriptomics profiles, respectively. As a proof-of-principle, potential causal effects of selenium on excreted cytokines concentrations were investigated using human peripheral blood mononuclear cells (PBMCs). ResultsMean selenium levels were 60.6 μg/L in Q1 and 122.0 μg/L in Q4. From 356 biomarkers and 20 clinical features, the penalized linear regression model yielded 44 variables with <5 % marginal false discovery rate as predictors of serum selenium. Biomarkers associated positively with selenium concentrations included: epidermal growth factor receptor (EGFR), IFN-gamma-R1, CD4, GDF15, and IL10. Biomarkers associated negatively with selenium concentrations included: PCSK9, TNFSF13, FGF21 and PAI. Additionally, 148 RNA transcripts were found differentially expressed between high and low selenium status (Padj.<0.05; log-fold-change<|0.25|). Enrichment analyses of the selected biomarkers and RNA transcripts identified similar enriched processes, including regulation processes of leukocyte differentiation and activation, as well as cytokines production. The mRNA expression of two selenoproteins (MSRB1 and GPX4) were strongly correlated with serum selenium, while GPX4, SELENOK, and SELENOS were associated with prognosis. In the in-vitro setting, PBMCs supplemented with selenium showed significantly lower abundance of several (pro-)inflammatory cytokines. ConclusionThese data suggest that immunoregulation is an important mechanism through which selenium might have beneficial roles in HF. The beneficial effects of higher serum selenium concentrations are likely because of global immunomodulatory effects on the abundance of cytokines. MSRB1 and GPX4 are potential modulators of and should be pursued in future research.

Serum selenium concentration in patients with autoimmune thyroid disease.

Abstract.

Follow-up of serum selenium concentrations in patients receiving selenium supplementation

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Serum selenium and prognosis in cardiovascular disease: results from the AtheroGene study

ObjectiveExperimental data suggest a protective role of the essential trace element selenium against cardiovascular disease (CVD), whereas epidemiological data remains controversial. We aimed to investigate the impact of serum selenium concentration in patients presenting with stable angina pectoris (SAP) or acute coronary syndrome (ACS) on long term prognosis. MethodsBaseline selenium concentration was measured in 1731 individuals (852 with SAP, and 879 with ACS). During a median follow-up of 6.1 years, 190 individuals died from cardiovascular causes. ResultsIn those ACS patients who subsequently died of cardiac causes, selenium levels were lower compared to survivors (61.0μg/L versus 71.5μg/L; P<0.0001). In a fully adjusted model, patients in the highest tertile of selenium concentration had a hazard ratio of 0.38 (95% CI: 0.16–0.91; P=0.03) as compared with those in the lowest. No association between selenium levels and cardiovascular outcome was observed in SAP. ConclusionsLow selenium concentration was associated with future cardiovascular death in patients with ACS.

Low serum selenium concentration in patients with cervical cancer

Selenium (Se), vitamin E and sulfur amino acids have long been considered to serve as antioxidants that complement one another. So is an essential component of intracellular and extracellular glutathione peroxidases 1. Vitamin E is a membraneassociated molecule that scavenges free radicals, preventing damage to membrane lipids 1. In addition to enzymatic antioxidative action, Se is included in other anticancerogenic mechanisms, among which activationinactivation of cell growth factor is the most important 2. In many publications low plasma Se concentrations correlated directly with an increased incidence of different carcinomas 34.

Serum selenium concentration in patients with asthma and its relationship to duration and severity

Serum selenium concentration in patients with asthma and its relationship to duration and severity

T04-P-009 Smoking and serum selenium concentration in patients with dyslipidemia

T04-P-009 Smoking and serum selenium concentration in patients with dyslipidemia

Decreased serum selenium concentrations in patients with Parkinson's disease

Selenium is an essential component of the antioxidant enzyme glutathione peroxidase. The activity of this enzyme is reduced in the substantia nigra of patients with Parkinson's disease (PD), but the results of studies on erythrocytes are controversial. We compared the serum levels of selenium and the 24 h urinary selenium excretion (measured by hydride generation atomic absorption spectrophotometry) in 29 PD patients and 30 matched controls. Serum selenium levels were significantly lower in PD patients than in controls (34.6 ± 2.35 and 45.2 ± 3.83 μg/l, p < 0.05) while urinary excretion was similar for both groups (47.1 ± 6.25 and 45.5 ± 5.38 μg/24 h). These values were not influenced by antiparkinsonian drugs, and they did not correlate with age, age at onset and duration of the PD, scores of the Unified PD Rating Scale or the Hoehn and Yahr staging in the PD group. These results might suggest a possible role of low serum selenium levels in the risk for, or a consequence of the oxidative stress in PD.

Low platelet glutathione peroxidase activity and serum selenium concentration in patients with chronic renal failure: relations to dialysis treatments, diet and cardiovascular complications.

1. Selenium status was investigated in patients with chronic renal failure, with special regard to its relations to the dialysis treatments, dietary habits and clinical signs of atherosclerosis. 2. Serum selenium concentration and platelet glutathione peroxidase activity were measured in 45 patients with chronic renal failure subdivided into three groups according to the type of treatment: 15 non-dialysed, 15 on haemodialysis, 15 on continuous ambulatory peritoneal dialysis. A 7-day diet history was carried out in all patients. Seventeen of the patients with chronic renal failure had clinically overt cardiovascular disease. Forty-five age-matched healthy subjects were considered as controls. 3. Both serum selenium concentration and platelet glutathione peroxidase were significantly reduced in all patients with chronic renal failure compared with control subjects; a direct and significant correlation was found between the two parameters. No differences in selenium status were observed among the non-dialysed, haemodialysis and continuous ambulatory peritoneal dialysis groups. No correlation between total calorie or protein intakes and selenium indices were observed. The chronic renal failure patients with cardiovascular complications showed a further significant reduction in both serum selenium concentration and platelet glutathione peroxidase activity as compared with the patients without cardiovascular complications; these two groups were similar with respect to the other well-known cardiovascular risk factors (age, smoking, plasma lipids, hypertension, body mass index). 4. It is concluded that a low selenium concentration is present in chronic renal failure, which is independent of dialysis and is accompanied by biological repercussion in terms of reduced platelet glutathione peroxidase activity.(ABSTRACT TRUNCATED AT 250 WORDS)

Serum selenium concentrations in patients with intestinal metaplasia and in controls

Serum selenium concentrations were measured in 126 matched sets of cases--patients with endoscopically proven intestinal metaplasia (IM) and two different controls, matched for age (+/- 3 years) and sex. The controls were either endoscopic controls (EC) who had endoscopically proven normal stomachs or non-endoscopic controls (NC), recruited from fracture and general surgical clinics. The cases and controls were recruited from four centres in the UK. Using a paired analysis, no significant difference was seen for IM vs EC either overall or between centres. However, these findings are compatible with reports of lower serum selenium in areas with a high risk of gastric cancer provided that selenium plays its role in the later stages of the disease.

Effects of selenium supplementation on blood and urine selenium levels and liver function in patients with primary biliary cirrhosis

To study the mechanism of the reduced serum selenium concentration in patients with liver damage we administered 200 μg (2.53 μmol) selenium daily as seleniumrich yeast to 8 patients with primary biliary cirrhosis and 8 healthy controls over 16 weeks. Initially selenium concentrations in serum were 24% lower ( P < 0.001) in patients than controls. During supplementation serum selenium levels increased in both groups but the difference between them persisted. Throughout the study whole blood selenium levels and glutathione peroxidase activities were also somewhat lower ( P = NS) in patients than controls. Selenium supplementation had no effect on whole blood glutathione peroxidase activities in either group. The basal 24 h urinary excretion of selenium was similar in both groups but was increased more by supplementation in patients than controls. Selenium administration did not influence the liver function of the patients. We conclude that impaired hepatic production of selenium-containing serum compounds is the most likely explanation for the reduced serum selenium concentration in patients with primary biliary cirrhosis.

Low serum selenium concentration in patients with cervical or endometrial cancer

Serum concentrations of selenium were determined in 37 patients with cervical and 64 patients with endometrial cancer. The patients had lower (P < 0.001) serum concentrations of selenium than the age-, weight- and place of residence-matched paired control women. There was no difference in the selenium concentration between various age groups or different clinical stages of cervical or endometrial cancer. A low serum concentration of selenium might be a contributing factor in uterine carcinogenesis.

Serum-selenium concentrations in patients with maple-syrup-urine disease and phenylketonuria under dieto-therapy

Serum-selenium concentrations were measured in 2 dietetically treated patients with maple-syrup-urine disease, in 11 dietetically treated patients with phenylketonuria, in 37 healthy children of different ages and in 183 healthy adults. The estimations were performed by instrumental neutron activation analysis. The values of the dietetically treated patients were much lower than those of healthy children of the same age group. Within 8 to 12 weeks the serumselenium concentrations decreased from normal values before therapy to very low values under dieto-therapy. During infancy the serum-selenium concentrations of healthy individuals show an increase to the adult range of values.